A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE MASKED, SHAM-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA
This research study is looking at a new treatment called RO7200220 for an eye problem called uveitic macular edema. This condition causes swelling at the back of the eye, which can blur your vision. The study aims to find out if this new medicine, given directly into the eye, can improve how well people see and reduce the swelling. Researchers will also check if the medicine is safe and how the body handles it. They'll compare the new medicine to a dummy treatment (placebo) to truly understand its effects. This is a large study involving many people to confirm if this treatment works.
At a glance
What is this study about?
This study is about a new medicine called RO7200220, which is being tested for people who have an eye condition called uveitic macular edema. Uveitis is a type of eye inflammation, and when this leads to swelling in the macula (a small but important part of the retina at the back of your eye responsible for sharp, central vision), it's called uveitic macular edema. This swelling can make your vision blurry or distorted.
The researchers want to see if this new medicine can help improve vision and reduce this swelling. The medicine will be given directly into the eye with an injection. To truly understand if the medicine works, some participants will receive the active medicine, while others will receive a 'sham' treatment, which looks like the real treatment but doesn't contain the active medicine. This is a common way to run studies and helps ensure the results are accurate. Neither you nor your doctor will know which treatment you are receiving until the study is over.
This is a 'Phase III' study, which means it's a large and important step in testing a new treatment. It's designed to confirm whether the medicine is effective and safe in a bigger group of people, after earlier studies showed promising signs. The main goal is to see if participants have a significant improvement in their eyesight after 16 weeks, by checking their ability to read letters on an eye chart.
Key takeaways
- This study tests a new eye medicine for uveitic macular edema.
- It aims to improve vision and reduce eye swelling.
- The medicine is given by injection into the eye.
- Some participants get the active medicine, some get a sham treatment.
- The study lasts about a year with regular check-ups.
- You can stop participating at any time.
Who may be eligible?
To be part of this study, you need to be at least 18 years old. Both men and women can take part. The study is specifically looking for people who have been diagnosed with uveitic macular edema.
There might be other health conditions or medications that could prevent you from joining, as the researchers need to make sure the study is safe for everyone involved and that the results of the new medicine can be clearly seen. For example, they might check for other eye conditions or if you're taking certain medicines that could interfere with the study drug.
Your eye doctor will carefully review your health and medical history to confirm if this study is suitable for you. They will explain all the requirements and help you understand if you meet the criteria to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of uveitic macular edema?
- Are you able to attend regular clinic visits for about a year?
- Are you comfortable with eye injections as part of the treatment?
What does participation involve?
If you decide to take part in this study, you will receive regular injections of either the study medicine (RO7200220) or a sham treatment directly into your eye. These injections will happen at specific times throughout the study period. You'll also have regular visits to the clinic where doctors will check your vision using eye charts and perform scans of your eye to measure the swelling. They will also take blood samples to see how your body handles the medicine.
Over the course of the study, you'll be asked to fill out questionnaires about your vision and how your eyes are feeling. The study will last for about a year (52 weeks), with frequent visits at the beginning and then less often later on. The total duration of your involvement will be around 52 weeks, starting from your first treatment.
Potential risks and benefits
Locations (5)
- —UnverifiedPortugal
- —UnverifiedPoland
- —UnverifiedItaly
- —UnverifiedNetherlands
- —UnverifiedAustria
Common questions
What is uveitic macular edema?
It's when inflammation in the eye (uveitis) causes swelling in the macula, a part of your retina essential for clear central vision, leading to blurry sight.
What does a 'sham' treatment mean?
A sham treatment looks exactly like the real treatment but doesn't contain the active medicine. It helps researchers safely see if the new medicine truly works better than no active treatment.
How will I know if the medicine is working?
Doctors will regularly check your vision using eye charts and take special scans of your eye to measure changes in swelling over time.
How long will I be in the study?
Your involvement in the study will last for about 52 weeks, which is roughly one year, with regular check-ups during that time.
Can I leave the study if I want to?
Yes, you are free to leave the study at any time, for any reason. Your decision will not affect your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.